Shares of Precipio (PRPO) surged over 200% on news that the company has launched it’s rapid COVID-19 test on the Amazon (AMZN) platform. According to the press release, Nirmidas’ test is available to POC healthcare providers with an Amazon business account.
The company successfully launched it’s 20 minute COVID-19 antibody test on Amazon’s business platform. Since the test is developed by Nirmidas Biotech, the company currently holds exclusive rights to distribute the product on Amazon’s platform.
This test is used to detect the existence of antibodies that have formed after a person has been exposed to the virus or has been vaccinated against it. Antibodies are the body’s own biological reaction to an infection or vaccine, and their formation kicks off the body’s mechanism of developing immunity to protect against future pathogens.
Knowing whether or not anyone has antibodies has two major advantages. Individuals who were inadvertently infected or who are aware that they were infected will first decide whether they have such antibodies.
This test provides a platform that can offer additional detail to those who are debating whether or not to get vaccinated. Second, people who have been vaccinated will use the test to see if the vaccine was effective and if the antibodies tested have lasted over time.
Should you invest in Precipio (PRPO) stock?
Shares of Precipio (PRPO) appear to be a very good investment option, with Wall Street analysts expecting its price to rise considerably in the next several months. The majority of the metrics point to this investment being highly attractive.
